[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"low-and-intermediate-risk-prostate-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:low-and-intermediate-risk-prostate-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100619078","micro-ultrasound-guided-focal-laser-ablation-for-intermediate-risk-prostate-cancer-safety--effectiveness-100619078",false,"NCT07339943","Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness","Micro-ultrasound-Guided Focal Laser Ablation (MicroUSgFLA) Treatment for Management of Intermediate-Risk Prostate Cancer: Evaluation of Safety and Effectiveness","MicroUSgFLA","Inclusion Criteria:\n\n* Men 40-80 years of age.\n* Histologically-proven intermediate-risk PCa (Gleason score 7, primary grade ≤ 4).\n* PCa clinical stage T1c or T2.\n* MRI\u002FMicroUS site suspicious for cancer or cancer mapped to one prostate lobe.\n* Maximum dimension of MRI\u002FMicroUS visible tumour ≤15mm.\n* Suspicious site on Prostate MRI\u002FMicroUS must coincide with sector positive for cancer on biopsy.\n* Prostate specific antigen (PSA) level \\\u003C 15 ng\u002FmL.\n* IPSS, ICIQ-UI-SF, IIEF-15 questionnaires completed prior to the procedure.\n* Life expectancy of greater than 10 years, based on co-morbidity not related to PCa.\n\nExclusion Criteria:\n\n* Maximum dimension of MRI\u002FMicroUS visible tumour \\> 15 mm.\n* Patients medically unfit for focal therapy of the prostate.\n* Patients who are unwilling or unable to give informed consent.\n* Patients who have received androgen suppression therapy.\n* Patients who have received or are receiving chemotherapy for prostate carcinoma.\n* Patients previously treated with surgery to the prostate (traditional, endoscopic or minimally invasive) including HIFU, TUNA, RITA, microwave, cryotherapy or any curative treatment.\n* Patients who have undergone radiation therapy for PCa or to the pelvis.\n* Any condition or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies).\n* Patients with a history of non-compliance with medical therapy and\u002For medical recommendations.\n* Patients who are unwilling or unable to complete the patient self-assessment questionnaires.\n* Chronic or acute prostatitis, neurogenic bladder, urinary tract infection, sphincter abnormalities, or any other symptom that prevents normal micturition.\n* Patients who have participated in a clinical study and\u002For received treatment with an investigational treatment and\u002For product within the past 90 days.\n* Patients with contraindication to MRI (i.e. pacemaker, hip prosthesis, severe claustrophobia, brain aneurysm clip, allergy to MRI contrast agent)","MALE","40 Years","85 Years",{"count":21,"type":22},7,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical research study is intended to show that Micro-Ultrasound Guided Focal Laser Ablation (MicroUSgFLA) is a safe procedure that can significantly postpone or eliminate the need for patients with intermediate-Risk prostate cancer (PCa) to undergo a definitive treatment (i.e., Radical Prostatectomy or Radiation Therapy) for their disease.",[28,29],"Prostate Cancer (Adenocarcinoma)","Low and Intermediate Risk Prostate Cancer",[31,32,33,34,35],"Micro-Ultrasound Guided Focal Laser Ablation","Focal Therapy","Focal Laser Ablation","Minimally Invasive Treatment","Laser Therapy","RECRUITING","2026-09-24",{"date":39,"type":40},"2026-09-25","ACTUAL",{"date":42,"type":40},"2025-04-30",{"date":44,"type":22},"2028-12-31",{"name":46,"class":47},"University Health Network, Toronto","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100335682","mri-guided-focal-laser-ablation-of-prostate-cancer-100335682","NCT03650595","MRI Guided Focal Laser Ablation of Prostate Cancer","MRgFLA","Inclusion Criteria:\n\n* Men 40-80 years of age\n* Histologically proven low-intermediate risk prostate carcinoma; (Gleason score ≤ 7, primary grade ≤ 4;)\n* Prostate cancer clinical stage T1c and T2\n* MR site suspicious for cancer or cancer mapped to one lobe of the prostate using the 3D hybrid TRUS device\n* Size of MR visible tumor \\\u003C20mm\n* Suspicious site on Prostate MRI must coincide with sector positive for cancer on biopsy\n* Prostate specific antigen (PSA) level \\\u003C15 ng\u002FmL\n* IPSS, ICIQ-UI-SF, IIEF complete prior to procedure\n* Life expectancy of greater than 10 years, based on co-morbidity not related to prostate cancer.\n\nExclusion Criteria:\n\n* Medically unfit for focal therapy of the prostate\n* Patients who are unwilling or unable to give informed consent;\n* Patients who have received androgen suppression therapy\n* Patients who have received or are receiving chemotherapy for prostate carcinoma;\n* Patients previously treated with surgery to the prostate (traditional, endoscopic or minimally invasive including HIFU, TUNA, RITA, microwave, cryotherapy or any curative treatment\n* Patients who have undergone radiation therapy for prostate cancer or to the pelvis\n* Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies);\n* Patients with a history of noncompliance with medical therapy and\u002For medical recommendations;\n* Patients who are unwilling or unable to complete the patient self-assessment questionnaires;\n* Chronic or acute prostatitis, neurogenic bladder, urinary tract infection, sphincter abnormalities, or any other symptom that prevents normal micturition.\n* Patients who have participated in a clinical study and\u002For received treatment with an investigational treatment and\u002For product within the past 90 days;\n* Patients with contraindication to MRI (i.e. pacemaker, hip prosthesis, severe claustrophobia, brain aneurysm clip, allergy to MRI contrast agent)\n* Any condition, or history of illness that, in the opinion of the investigator will confound or increase the patient risk during the study","80 Years",{"count":58,"type":22},102,[25],"This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate. The results will be evaluated by repeated MRI and prostate biopsy. Previous prospective development study demonstrated that FLA may be a viable option for men with low-intermediate risk prostate cancer. The vast majority of patients undergoing this treatment experienced minimal side effects with no peri-operative complications. Over 80% of patients treated with MRgFLA remain on AS and were able to avoid radical therapy at mean follow up duration of 3 years.",[62,29],"Prostate Cancer",[64,33,65],"MRI","MR-Guided Focal Laser Ablation","2026-06-03",{"date":68,"type":40},"2026-06-05",{"date":70,"type":40},"2018-03-29",{"date":72,"type":22},"2028-06-30",{"name":46,"class":47}]